Medicare Enrolled
Dr. David Vanderweele, M.D.
Medical Oncology · Chicago, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Vanderweele from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Vanderweele?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Vanderweele
Dr. David Vanderweele is a medical oncology specialist in Chicago, IL, with 18 years of NPI registration. Based on federal Medicare data, Dr. Vanderweele performed 43,641 Medicare services across 1,413 unique beneficiaries.
Between the years covered by Open Payments, Dr. Vanderweele received a total of $21,120 from 8 pharmaceutical and/or device companies across 38 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Vanderweele is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 16% volume in IL
$21,120 industry payments
Medicare Practice Summary
Medicare Utilization ↗43,641
Medicare services
Top 16% in IL for medical oncology
1,413
Unique beneficiaries
$23
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,424 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 9,180 | $19 | $58 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
7,020 | $38 | $170 |
| Pembrolizumab injection (Keytruda) | 5,800 | $43 | $171 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
4,950 | $0 | $7 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
4,102 | $0 | $38 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
2,400 | $0 | $2 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
1,870 | $36 | $134 |
| Bevacizumab biosimilar injection, 10 mg An injection of bevacizumab-awwb, a biosimilar medication, administered in a 10 mg dose. |
1,459 | $23 | $194 |
| Injection, atropine sulfate, 0.01 mg | 1,060 | $0 | $1 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
1,044 | $5 | $174 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
662 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 660 | $1 | $76 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
628 | $97 | $323 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 488 | $133 | $2,712 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
386 | $2 | $8 |
| Injection, irinotecan, 20 mg | 228 | $2 | $45 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
191 | $13 | $143 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
168 | $28 | $237 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
167 | $109 | $940 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
165 | $4 | $10 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
156 | $87 | $821 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
141 | $12 | $88 |
| Injection, granisetron hydrochloride, 100 mcg | 130 | $0 | $5 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
80 | $60 | $326 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
64 | $52 | $410 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
55 | $24 | $203 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
53 | $17 | $129 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
46 | $213 | $1,618 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
40 | $23 | $215 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
35 | $134 | $505 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
33 | $54 | $464 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
30 | $144 | $434 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
23 | $46 | $393 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
20 | $75 | $219 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
17 | $1 | $7 |
| New patient office visit, complex (60-74 min) | 14 | $184 | $625 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
14 | $2 | $20 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
13 | $72 | $110 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
13 | $27 | $338 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
13 | $32 | $57 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
12 | $109 | $500 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
11 | $15 | $109 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.2% high complexity
91.9% medium
2.9% routine
Industry Payment Transparency
Open Payments through 2023 ↗$21,120
Total received (2018-2023)
Avg $3,520/year across 6 years
Top 21% in IL for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
8
Companies
38
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$14,497 (68.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$5,345 (25.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,279 (6.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2023
$4,937
2022
$8,426
2021
$5,345
2020
$1,591
2019
$407
2018
$414
Payments by company (2023)
Consulting
Speaking
Meals & Travel
Research
Bayer Healthcare Pharmaceuticals Inc.
$4,695
PFIZER INC.
$135
Exelixis Inc.
$107
Top 3 companies account for 100.0% of 2023 payments
All-time payments by company (2018-2023) ›
Bayer HealthCare Pharmaceuticals Inc.
$8,302
Exelixis Inc.
$5,452
Bayer Healthcare Pharmaceuticals Inc.
$4,695
Clovis Oncology, Inc.
$1,500
GENZYME CORPORATION
$821
PFIZER INC.
$135
AstraZeneca Pharmaceuticals LP
$124
Genentech, Inc.
$91
Top 3 companies account for 87.4% of all-time payments
Associated products mentioned in payments ›
CABOMETYX · LYNPARZA · NO PRODUCT DISCUSSED · Nubeqa · Rubraca
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (69%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Medical oncologists within 10 mi
78
Per 100K population
1.5
County median income
$81,797
Nearest hospital
NORTHWESTERN MEMORIAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Vanderweele is a mixed practice specialist, with above-average Medicare volume (top 16% in IL), with consulting-driven industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Vanderweele experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Vanderweele performed 9,180 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Vanderweele receive payments from pharmaceutical companies?
Yes. Dr. Vanderweele received a total of $21,120 from 8 companies across 38 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Vanderweele's costs compare to other medical oncologists in Chicago?
Dr. Vanderweele's average Medicare payment per service is $23. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Vanderweele) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Chicago
Browse medical oncologists in Chicago ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in IL
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in IL
Which IL medical oncologists receive the most from drug and device companies.
By company
Bayer HealthCare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer HealthCare Pharmaceuticals Inc.
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc.
By company
Bayer Healthcare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer Healthcare Pharmaceuticals Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology